Abstract:Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.

Endoscopic removal of rectal leiomyoma: case report.

Liquid biopsy: current technology and clinical applications

Liquid biopsy: paving a new avenue for cancer research

The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Liquid biopsy, an innovation of modern medicine

LIQUID BIOPSY: A NON-INVASIVE TOOL TO DETECT CANCER AT AN EARLY STAGE

Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

[Criteria for quantification and characterization of aneurysms of the abdominal aorta using ultrasonography. The AFFCA study. French Association of Continuous Education in Angiology].

Liquid biopsy: novel technologies and clinical applications

Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer

Liquid Biopsies, Novel Approaches and Future Directions

Liquid Biopsy in Gastrointestinal Cancers

The three-hour conversation ratio: a test for hyperthyroidism.

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)

Liquid biopsy for breast cancer and other solid tumors: a review of recent advances

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Liquid biopsy: unlocking the potentials of cell-free DNA